ACHC Q3 2026 deep dive: new facility ramp and cost discipline drive guidance increase

Behavioral health company Acadia Healthcare (NASDAQ:ACHC) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 5.1% year on year to $895.3 million. The company’s full-year revenue guidance of $3.45 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.60 per share was 29.2% above analysts’ consensus estimates.

Is now the time to buy ACHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Acadia Healthcare’s third quarter results drew a significant positive market reaction, as the company surpassed Wall Street’s revenue and profit expectations. Management attributed the performance to strong growth in patient volumes, effective cost controls, and accelerated operational milestones for new facilities. CEO Debbie Osteen highlighted the impact of recently opened acute care sites and operational improvements at legacy locations, emphasizing that “solid growth in patient volumes and strong revenue per patient day” were central to the quarter’s outcome.

Looking forward, Acadia Healthcare’s updated guidance reflects expected contributions from recently added acute facilities and ongoing efficiency gains. Management pointed to anticipated occupancy increases and cost reductions at new sites as primary drivers for next year’s outlook. CFO David Duckworth said, “A key part of the $60 million is the startup losses that we have incurred this year and the progress that we can make on just getting those facilities not only ramped up to a break-even occupancy level… but also just manage the cost structure as they ramp up.”

Key insights from management’s remarks

Management credited the quarter’s momentum to new facility ramp, operational efficiency, and targeted investments in leadership and technology.

• New acute facilities ramping: Acadia opened its fourth acute facility of the year, Coastal Pines Behavioral Health, and now counts 16 new openings since 2023. These sites are reaching licensing and accreditation faster, supporting quicker patient service and revenue contributions.
• Legacy site performance: Existing facilities, which make up the bulk of Acadia’s footprint, delivered steady volume growth and benefited from targeted efforts to address underperforming sites. Management cited detailed improvement plans and increased visibility at the facility level as contributing factors.
• Operational efficiency initiatives: The company achieved cost savings by reducing startup losses and optimizing regional leadership structures, particularly in the CTC (Comprehensive Treatment Center) segment. Management is deploying technology and analytics to further streamline revenue cycle and documentation processes.
• Service line stabilization: Specialty and CTC revenue stabilized sequentially, with management noting improved admissions trends into the fall. Ongoing regional strategies and cost management are seen as key to supporting future growth in these segments.
• Supplemental payment opportunities: Acadia is monitoring potential regulatory approvals in states like Florida and Ohio that could add over $20 million in incremental EBITDA, though these upside scenarios are not included in current guidance.

Drivers of future performance

Acadia’s outlook is driven by ramping new facility contributions, ongoing cost discipline, and expectations for continued demand in behavioral health services.

• New facility ramp-up: Management expects recently opened acute facilities to contribute meaningfully to adjusted EBITDA in the coming year, as occupancy improves and startup losses diminish. Duckworth noted a projected reduction in startup losses from $45 million to $10 million, as these sites approach break-even occupancy levels (around 40%).
• Legacy site optimization: The company is targeting further volume and margin gains from its legacy locations, with dedicated improvement plans for underperforming facilities and continued investment in technology to support operational efficiency and care quality.
• Regulatory and payer trends: Acadia sees continued strong demand for behavioral health services, but cautions that Medicaid policy changes and payer dynamics could affect patient mix and reimbursement. Management believes most Medicaid patients will remain exempt from new work requirements, minimizing disruption, but is closely watching state-level developments.

Catalysts in upcoming quarters

Going forward, the StockStory team is monitoring (1) the ramp-up pace and financial contribution of new acute facilities as they scale occupancy, (2) operational efficiency and cost management efforts, particularly in underperforming segments, and (3) the outcome of pending supplemental payment programs in Florida and Ohio. Execution in these areas will be critical to sustaining improved profitability and meeting raised financial guidance.

Acadia Healthcare currently trades at $35.86, up from $32.25 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.